- Home
- TSAT vs ITOS Comparison
TSAT vs ITOS Comparison
Compare TSAT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- ITOS
- Stock Information
- Founded
- TSAT 1969
- ITOS 2011
- Country
- TSAT Canada
- ITOS United States
- Employees
- TSAT N/A
- ITOS N/A
- Industry
- TSAT Metal Fabrications
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSAT Industrials
- ITOS Health Care
- Exchange
- TSAT Nasdaq
- ITOS Nasdaq
- Market Cap
- TSAT 233.1M
- ITOS 381.2M
- IPO Year
- TSAT 1996
- ITOS 2020
- Fundamental
- Price
- TSAT $23.41
- ITOS $10.26
- Analyst Decision
- TSAT
- ITOS Hold
- Analyst Count
- TSAT 0
- ITOS 6
- Target Price
- TSAT N/A
- ITOS $10.60
- AVG Volume (30 Days)
- TSAT 170.5K
- ITOS 793.1K
- Earning Date
- TSAT 08-13-2025
- ITOS 08-07-2025
- Dividend Yield
- TSAT N/A
- ITOS N/A
- EPS Growth
- TSAT N/A
- ITOS N/A
- EPS
- TSAT N/A
- ITOS N/A
- Revenue
- TSAT $372,642,710.00
- ITOS $35,000,000.00
- Revenue This Year
- TSAT N/A
- ITOS N/A
- Revenue Next Year
- TSAT N/A
- ITOS N/A
- P/E Ratio
- TSAT N/A
- ITOS N/A
- Revenue Growth
- TSAT N/A
- ITOS 177.89
- 52 Week Low
- TSAT $7.21
- ITOS $4.80
- 52 Week High
- TSAT $27.45
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- TSAT 65.95
- ITOS 66.97
- Support Level
- TSAT $25.26
- ITOS $10.05
- Resistance Level
- TSAT $27.45
- ITOS $10.21
- Average True Range (ATR)
- TSAT 1.70
- ITOS 0.13
- MACD
- TSAT 0.01
- ITOS -0.06
- Stochastic Oscillator
- TSAT 66.48
- ITOS 81.48
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.